(Q28258977)

2

0 references

Bindia Jharap

3

0 references

Peer de Graaf

4

0 references

Chris J J Mulder

Nature Reviews Gastroenterology & Hepatology

5

0 references

language of work or name

English

0 references

publication date

December 2007

0 references

published in

0 references

volume

4

0 references

issue

12

0 references

page(s)

686-94

0 references

cites work

Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

Differential Control of Cell Cycle, Proliferation, and Survival of Primary T Lymphocytes by Purine and Pyrimidine Nucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Safety of thiopurines in the treatment of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Pharmacokinetic considerations in the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

The clinical pharmacology of 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

High variation of tioguanine absorption in patients with chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Differences between children and adults in thiopurine methyltransferase activity and metabolite formation during thiopurine therapy: possible role of concomitant methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-Thioguanine alters the structure and stability of duplex DNA and inhibits quadruplex DNA formation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Concurrent unilateral chromatid damage and DNA strand breakage in response to 6-thioguanine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Structure and dynamics of thioguanine-modified duplex DNA

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

TPMT in the treatment of Crohn's disease with azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Selective inhibition of inflammatory gene expression in activated T lymphocytes: a mechanism of immune suppression by thiopurines

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase).

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Lack of association between the ITPA 94C>A polymorphism and adverse effects from azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Small bowel malignancy at diagnosis of coeliac disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Remission maintenance by tioguanine in chronic active Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

On the limitation of 6-tioguaninenucleotide monitoring during tioguanine treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Drug-induced hepatotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Some cases demonstrating the clinical usefulness of therapeutic drug monitoring in thiopurine-treated inflammatory bowel disease patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Nodular regenerative hyperplasia: not all nodules are created equal.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine and UVA light generate mutagenic oxidative DNA damage

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Exposure to thiopurine drugs through breast milk is low based on metabolite concentrations in mother-infant pairs

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Azathioprine and breastfeeding-is it safe?

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Rational dosing of azathioprine and 6-mercaptopurine

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021

Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPGASTHEP1000

7 January 2021